Xcelerate, Inc. Signs Letter of Intent to Explore Business Relationship with HS Pharmaceuticals

Rhea-AI Summary

Xcelerate, Inc. (OTC pink sheets: XCRT) announced signing a non-binding letter of intent (LOI) to explore a business combination with HS Pharmaceuticals, LLC, based in Greenville, SC. HS Pharmaceuticals has a platform of patented technologies focusing on immunotherapy alternatives and infection treatment. Xcelerate aims to leverage HS’s research and intellectual property through due diligence led by its team of clinicians and researchers. This strategic move underscores Xcelerate's commitment to innovative acquisitions in early-stage medical technology.

Positive

• Potential synergy with HS Pharmaceuticals could enhance Xcelerate's R&D capabilities in medical technology.
• HS Pharmaceuticals' patented technologies may provide Xcelerate with a competitive edge in healthcare applications.

Negative

• The LOI is non-binding; actual consolidation is uncertain and may not occur.
• Potential risks and uncertainties in integrating HS Pharmaceuticals' technologies with Xcelerate's operations.

MAULDIN, S.C., May 6, 2021 /PRNewswire/ -- Xcelerate, Inc. (OTC pink sheets: XCRT) today announced it has signed a non-binding letter of intent to pursue a business combination with HS Pharmaceuticals, LLC of Greenville, SC.  Over the past 14 years HS Pharmaceuticals has developed a platform of novel technologies centered around their patented and patent pending silicate particle research. Their research, in conjunction with leading universities and research facilities, has led to developments in healthcare in areas such as immunotherapy alternatives, topical therapies to combat infection and bacteria as well bone regeneration. For more information visit their website www.hspharma.com.

The LOI provides for XCRT to undertake its due diligence wherein its world-renowned team of clinicians and researchers will review HS Pharmaceuticals' operations, structure, and intellectual property. "During this process, Xcelerate, a rapidly emerging leader in assembling and developing early-stage medical technology, will determine how and in what structure HS Pharmaceuticals research and IP would fit within its business plan.  The potential consolidation with HS Pharmaceuticals is further evidence that Xcelerate seeks to continue making headway in finding innovative acquisitions within the patent/engineering world.  We remain focused on joining early-stage medical technology companies in a setting of controlled clinical care where these new developments can be trialed, tested and applied," said Xcelerate CEO Michael F. O'Shea.

SAFE HARBOR

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.

Media contact: Justin Baronoff 561-750-9800; justin@transmediagroup.com.

View original content:http://www.prnewswire.com/news-releases/xcelerate-inc-signs-letter-of-intent-to-explore-business-relationship-with-hs-pharmaceuticals-301286074.html

SOURCE Xcelerate, Inc.

FAQ

What is Xcelerate, Inc.'s recent announcement about?

Xcelerate, Inc. announced a non-binding letter of intent to explore a business combination with HS Pharmaceuticals, LLC.

What technologies does HS Pharmaceuticals focus on?

HS Pharmaceuticals specializes in immunotherapy alternatives, topical therapies for infections, and bone regeneration.

What does the letter of intent mean for Xcelerate, Inc. and HS Pharmaceuticals?

The letter of intent indicates Xcelerate's interest in a potential business consolidation with HS Pharmaceuticals, subject to due diligence.

What are the potential benefits of Xcelerate's deal with HS Pharmaceuticals?

The deal may provide Xcelerate access to innovative technologies and enhance its competitive position in the medical technology market.

What risks are associated with Xcelerate's letter of intent with HS Pharmaceuticals?

The non-binding nature of the LOI means that the actual consolidation is uncertain, and there are inherent risks in integrating new technologies.